ArticleInternational journal of environmental research and public health2015
PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
Article in International journal of environmental research and public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Exploring the oncogenic mechanism of plasmacytoma variant translocation 1 (PVT1) gene in solid cancers; emphasis on microRNA regulation pathways.Cancer cell international · 2026Review
- LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target.Molecular cancer · 2026Review
- Combining Serum PVT1 Exon 4A and Exon 9 with Serum Prostate-Specific Antigen Shows Potential for Improving Identification and Risk Stratification of Prostate Cancer.Cancer management and research · 2026Article
- Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1 (Genes & diseases · 2023Review
- lncRNA PVT1: a novel oncogene in multiple cancers.Cellular & molecular biology letters · 2022Review
- Role of MicroRNAs in Neuroendocrine Prostate Cancer.Non-coding RNA · 2022Review
- LncRNAs and the Angiogenic Switch in Cancer: Clinical Significance and Therapeutic Opportunities.Genes · 2022Review
- Long non-coding RNA in prostate cancer.American journal of clinical and experimental urology · 2022Review
- Long Non-Coding RNAs at the Chromosomal Risk Loci Identified by Prostate and Breast Cancer GWAS.Genes · 2021Review
- Article
- MicroRNA-1205 Regulation of FRYL in Prostate Cancer.Frontiers in cell and developmental biology · 2021Article
- Prostac: A New Composite Score With Potential Predictive Value in Prostate Cancer.Frontiers in oncology · 2021Article
- Biomarkers in Colorectal Cancer: Current Research and Future Prospects.International journal of molecular sciences · 2020Review
- Population Differentiation at the PVT1 Gene Locus: Implications for Prostate Cancer.G3 (Bethesda, Md.) · 2020Article
- Oxytocin and oxytocin receptor alterations, decreased survival, and increased chemoresistance in patients with pancreatic cancer.Hepatobiliary & pancreatic diseases international : HBPD INT · 2020Article
- Oncogenic Role of PVT1 and Therapeutic Implications.Frontiers in oncology · 2020Review
- Editorial: PVT1 in Cancer.Frontiers in oncology · 2020Article
- Article
- Interactions ofCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of the 8q24 human chromosomal region. The non-protein coding gene locus Plasmacytoma Variant Translocation 1 (PVT1) is located at 8q24 and is overexpressed in PCa and, therefore, is also a candidate biomarker to explain the well-known disparity in this group. PVT1 has at least 12 exons that make separate transcripts which may have different functions, all of which are at present unknown in PCa. Our aim was to determine if any PVT1 transcripts play a role in aggressiveness and racial disparity in PCa. We used a panel of seven PCa cell lines including three derived from MoAA. Ribonucleic acid extraction, complementary deoxyribonucleic acid synthesis, and quantitative polymerase chain reaction (qPCR) were performed to evaluate expression of all 12 PVT1 exons. Each qPCR was performed in quadruplicates. At least four separate qPCR experiments were performed. Expression of PVT1 exons was inconsistent except for exon 9. There was no significant difference in exon 9 expression between cell lines derived from Caucasian males (CM), and an indolent cell line derived from MoAA. However, exon 9 expression in the aggressive MDA PCa 2b and E006AA-hT cell lines derived from MoAA was significantly higher than in other cell lines. Consequently, we observed differential expression of exon 9 of PVT1 in a manner that suggests that PVT1 exon 9 may be associated with aggressive PCa in MoAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.